Search

Displaying results 3561 - 3570 of 7603 in total
  1. Drug

    Valdecoxib

    go.drugbank.com/drugs/DB00580
    ApprovedWithdrawn

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

  2. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition

  3. Drug

    Tirapazamine

    go.drugbank.com/drugs/DB04858
    Investigational

    Tirapazamine entered phase III testing in 2006 for patients with head and neck cancer and gynecological cancer, as well as for other solid tumor cancer types. … For all these reasons, the combination of tirapazamine with other anticancer treatments is highly recommended.

  4. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  5. Drug

    Borage oil

    go.drugbank.com/drugs/DB11238
    Approved

    GLA, which accounts for approximately 24% of the oil, is converted to dihomo-γ-linolenic acid (DGLA) which acts as a precursor to anti-inflammatory mediators such as 1-series prostaglandins and the 3-series … Borage oil may be found in foods or in skin care products.

  6. Drug

    Bucetin

    go.drugbank.com/drugs/DB13278
    ApprovedWithdrawn

    Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]

  7. Drug

    Suprofen

    go.drugbank.com/drugs/DB00870
    ApprovedWithdrawn

    It is no longer approved for use in the United States.

  8. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    As many tumors become more aggressive, invasive, and malignant, researchers have found that N-cadherin is expressed in greater amounts, making it an important target for developing anti-cancer treatments

  9. Drug

    WU-NK-101

    go.drugbank.com/drugs/DB18350
    Investigational

    WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product

  10. Drug

    MK-7145

    go.drugbank.com/drugs/DB11968
    Investigational

    MK-7145 has been used in trials studying the treatment of Hypertension and Renal Insufficiency.